Literature DB >> 16828151

Multiple vaccine and pyridostigmine interactions: effects on EEG and sleep in the common marmoset.

K E Williams1, T M Mann, S Chamberlain, A Smith, S Wilson, G D Griffiths, A P Bowditch, E A M Scott, P C Pearce.   

Abstract

Following active service during the 1990/1991 Gulf conflict, a number of UK and US veterans presented with a diverse range of symptoms, collectively known as Gulf Veterans' Illnesses (GVI). The administration of vaccines and/or the pretreatment against possible nerve agent poisoning, pyridostigmine bromide (PB), given to Armed Forces personnel during the Gulf conflict has been implicated as a possible factor in the aetiology of these illnesses. The possibility that long-term health effects may result from the administration of these vaccines (anthrax, pertussis, plague, yellow fever, polio, typhoid, tetanus, hepatitis B, meningococcal meningitis and cholera) and/or PB, have been investigated using a non-human primate model, the common marmoset. This paper reports the results from two aspects of the study, brain electrical activity (EEG, collected during performance of a touchscreen mediated discrimination task) and sleep. There were no marked long-term changes in EEG or sleep patterns that could be attributed to vaccines and/or PB administration. The changes that were detected were predominantly time related and independent of treatment. Where statistical differences were detected between treatments, the magnitudes of the difference were relatively minor and therefore not regarded as having long term biological significance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828151     DOI: 10.1016/j.pbb.2006.05.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  1 in total

1.  Sickness absence of multivaccinated employees at Porton Down: a retrospective cohort study.

Authors:  E Hugh Dyson; Andrew J H Simpson; Robert J Gwyther; Paul Rice
Journal:  Occup Environ Med       Date:  2007-07       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.